Core Points - RAPT Therapeutics, Inc. announced a public offering of 8,333,334 shares of common stock priced at $30.00 per share, with expected gross proceeds of approximately $250 million [1] - The offering includes a 30-day option for underwriters to purchase an additional 1,250,000 shares at the public offering price [1] - The offering is expected to close on or about October 23, 2025, subject to customary closing conditions [1] Company Overview - RAPT Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory and immunological diseases [5] - The company utilizes proprietary expertise in immunology to create novel therapies aimed at modulating immune responses [5] Offering Details - The offering is conducted under a shelf registration statement filed with the SEC, which was declared effective on August 17, 2023 [3] - Joint bookrunning managers for the offering include Leerink Partners, TD Cowen, Guggenheim Securities, Wells Fargo Securities, and LifeSci Capital [2]

Core Insights - RAPT Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory and immunological diseases [2] Group 1: Company Overview - RAPT Therapeutics specializes in discovering, developing, and commercializing novel therapies aimed at modulating immune responses related to inflammatory and immunological diseases [2] - The company leverages proprietary expertise in immunology to create innovative treatment options for patients [2] Group 2: Upcoming Events - RAPT management will participate in several investor conferences in September 2025, including: - 2025 Wells Fargo Healthcare Conference on September 3, 2025, at 12:45 p.m. ET [3] - Cantor Global Healthcare Conference on September 4, 2025, at 1:00 p.m. ET [3] - H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025, at 9:00 a.m. ET [3] - Stifel 2025 Virtual Immunology & Inflammation Forum on September 15, 2025, at 9:30 a.m. ET [3] - Live webcasts and archived recordings of these events will be available on the RAPT Therapeutics website [1]